The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dörner, T.
Right arrow Articles by Lipsky, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dörner, T.
Right arrow Articles by Lipsky, P. E.
The Journal of Immunology, 1999, 163: 1027-1036.
Copyright © 1999 by The American Association of Immunologists

Ig {lambda} and Heavy Chain Gene Usage in Early Untreated Systemic Lupus Erythematosus Suggests Intensive B Cell Stimulation1

Thomas Dörner, Nancy L. Farner and Peter E. Lipsky2

Department of Internal Medicine and The Harold C. Simmons Arthritis Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75235


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To determine the distribution of V{lambda} and J{lambda} as well as VH and JH gene usage in a patient with systemic lupus erythematosus (SLE), productive and nonproductive VJ and V(D)J rearrangements were amplified from individual peripheral CD19+ B cells and were analyzed. No differences in the V{lambda} and J{lambda} or the VH and JH gene usage in the nonproductive gene repertoire of this SLE patient were found compared with the distribution of genes found in normal adults, whereas marked skewing of both V{lambda} and VH was noted among the productive rearrangements. The distribution of productive V{lambda} rearrangements was skewed, with significantly greater representation of the J{lambda} distal cluster C V{lambda} genes and the V{lambda} distal J{lambda}7 element, consistent with the possibility that there was receptor editing of the V{lambda} locus in this patient. Significant bias in VH gene usage was also noted with VH3 family members dominating the peripheral B cell repertoire of the SLE patient (83%) compared with that found in normal subjects (55%; p < 0.001). Notably, a clone of B cells employing the VH3-11 gene for the heavy chain and the V{lambda}1G segment for the light chain was detected. These data are most consistent with the conclusion that extreme B cell overactivity drives the initial stages of SLE leading to remarkable changes in the peripheral V gene usage that may underlie on fail to prevent the emergence of autoimmunity.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Systemic lupus erythematosus (SLE)3 is an autoimmune disease characterized by the production of multiple autoantibodies, especially anti-dsDNA Abs (1). Despite intensive study, the factors that lead to the production of autoantibodies in SLE remain unknown. The possibility that there are abnormalities in the Ig repertoire of patients with SLE has not been completely examined. It is not known whether an aberrant V(D)J recombination process itself predisposes to the generation of autoreactive Abs, as has been suggested for A30/J{kappa}2 rearrangements (2), or, alternatively, whether abnormalities in somatic hypermutation and/or subsequent selective influences can lead to the generation of autoantibodies.

Recently, we found that the V{kappa}J{kappa} recombination process, as judged by analysis of nonproductive V{kappa}J{kappa} rearrangements in an untreated SLE patient, appeared to be comparable to that in normal subjects (3). However, striking differences in the productive V{kappa} repertoire of this patient were noted, with enhanced usage of the J{kappa} distal V{kappa} genes and a marked increase in the usage of J{kappa}5, the most V{kappa} distal J{kappa} gene. These data suggested that the replacement of primary V{kappa} rearrangements by subsequent rearrangements (receptor editing) was more frequent in this SLE patient than had been observed in normal subjects (4). Although these results were obtained from a single patient, they were so strikingly different from a previous V{kappa}J{kappa} repertoire analysis in normal subjects (4) that a more extensive examination of this patient was conducted. Specifically an analysis of the V{lambda} and VH repertoire was conducted because of the possibility that V{lambda} and VH receptor editing in SLE might also be abnormal.

The distribution of V{lambda}/J{lambda} and VH/JH rearrangements in the normal Ig gene repertoire has been delineated recently (5, 6, 7). Therefore, to determine whether there was increased receptor editing of V{lambda} and VH genes in SLE or other abnormalities in the V gene repertoire, the current study analyzed and compared the usage of V{lambda}/J{lambda} and VHDJH gene elements in this same untreated SLE patient with the repertoire of normal donors. The distribution of VH and V{lambda} genes in the nonproductive repertoire of this SLE patient was compared with that in normal subjects, suggesting that there were no major molecular abnormalities in V{lambda}J{lambda} recombination. Striking abnormalities in the distribution of V{lambda} genes were noted in the productive repertoire, however, consistent with accentuated receptor editing of V{lambda} genes. In addition, although no evidence of increased receptor editing of VH genes was found, skewing of the expressed VH repertoire, increased somatic hypermutation, and clonal expansion was detected. These results are consistent with the conclusion that there is marked overactivity of B cells in early SLE that could contribute to the production of autoantibodies.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Patient material

The method of cell purification, B cell staining and sorting, as well as the primer extension preamplification procedure have been reported in detail recently (6, 7). Briefly, B cells were obtained from a 54-yr-old Hispanic man with SLE, who was previously undiagnosed. Features of SLE included a typical butterfly rash, hyperkeratotic lesions of SCLE, increased fatigue, intermittent episodes of fever, and arthralgias of the proximal interphalangeal joints. The antinuclear Ab titer was 1:2560 (speckled pattern), and anti-Ro, -La, and -RNP Abs were present, whereas anti-dsDNA Abs were repeatedly absent. The patient did not have hypergammaglobulinemia. It should be noted that titers of these autoantibodies remained comparable for the next 1.5 yr. Clinically, disease manifestations began about 4 wk before the B cells were sorted, as evidenced by the onset of a typical rash. The patient had noted photosensitivity for many years. At this particular time point, there were no signs or symptoms of another connective disease. A reduction of complement factors C3 (62.6 mg/dl; normal, 65–203) and C4 (<10 mg/dl; normal, 16–54) was also found. The white blood cell count was 3.8 x 103/µl, with 20% lymphocytes. Because of the decreased blood cell count, only CD19+ B cells were isolated. The patient fulfilled the revised criteria for classification of SLE (8).

FACS sorting and PCR amplification

Altogether 276 individual CD19+ B cells were sorted into wells of 96-well plates (Robbins Scientific, Sunnyvale, CA) using a FACStar Plus flow cytometer with an automated single cell deposit unit (Becton Dickinson, Mountain View, CA) as described previously (4, 5, 6, 7). Twelve wells (four per plate) that received no cells were used as negative controls. Rearranged V{lambda}J{lambda} and VHDJH genes were then amplified as described recently (5, 6, 7). The PCR amplification included a primer extension preamplification (7) and subsequent nested PCR steps (5, 7). After column purification of PCR products (GenElute Agarose Spin Column, Supelco, Bellefonte, PA), all PCR products were directly sequenced using the ABI Prism Dye Termination Cycle Sequencing Kit (Perkin-Elmer, Palo Alto, CA) and analyzed with an automated sequencer (ABI Prism 377, Perkin-Elmer). Sequences were analyzed using the V BASE Sequence Directory (9) to identify the respective germline gene. For the identification of the underlying germline segments, the software programs GeneWorks (release 2.45; IntelliGenetics, Mountain View, CA) and Sequencher (Gene Codes, Ann Arbor, MI) were employed.

The usage of VH and JH genes as well as V{lambda} and J{lambda} rearrangements segments from two healthy normal male donors (26 and 45 yr old) that had been published previously (5, 6) served as a comparison. Both the nonproductive and productive repertoires of these two normal, age-disparate donors exhibited an overall similar usage of V and J gene elements.

Determination of Taq polymerase fidelity and the frequency of potential sequence errors

The maximal PCR error rate for this analysis has been documented to be 1.2 x 10-3 mutations/bp, and the minimal error to be 1 x 10-4 (5, 10).

Statistical analysis

Sequences were analyzed with the {chi}2 test to compare the differences in the distribution of particular gene segments as well as mutational frequencies between the V{lambda}J{lambda} and VHDJH rearrangements of the SLE patient and the normal subjects. The goodness of fit {chi}2 test (11) was used to compare the actual distribution of V{lambda} and J{lambda} as well as the VH and JH family gene usage in the SLE patient to the frequency that might be expected based upon the number of genes in the genome (6). P < 0.05 was considered statistically significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
V{lambda} gene usage in SLE

A total of 104 productive and 58 nonproductive V{lambda}J{lambda} rearrangements were analyzed. The distribution of individual V{lambda} families is shown in Table IGo. Of importance, no major differences in V{lambda} gene usage between the nonproductive repertoire of the SLE patient and that of the normal subjects was found. Some minor differences between the nonproductive repertoire of normal subjects and that of the SLE patient were noted. For example, V{lambda}6 genes were found significantly more often in the nonproductive repertoire of the SLE patient (9%) than expected by chance alone, whereas this V{lambda} gene family was not over-represented in the nonproductive repertoire of the normal subjects (3.6%).


View this table:
[in this window]
[in a new window]
 
Table I. Comparison of V{lambda} gene family usage in an SLE patient and in normals

 
Of note, however, significant differences were detected when the productive repertoires of the SLE patient and those of the normal subjects were compared. Thus, V{lambda}4 family members occurred significantly more often in the productive repertoire of the normal subjects than in that of the SLE patient (5.8 vs 0%; p = 0.012), whereas members of the V{lambda}6 (p < 0.001) and V{lambda}8 (p < 0.001) families were more frequently employed in the productive repertoire of the SLE patient. These differences suggest that factors dependent on expression of a productively rearranged V{lambda} gene may have influenced the distribution of V{lambda} genes in the SLE patient.

J{lambda} gene usage in SLE

The distribution of rearranged J{lambda} elements in the SLE patient is summarized in Table IIGo. Of note, the usage of J{lambda}2/3 and J{lambda}7 was significantly different between the nonproductive repertoire of the SLE patient and that of the normal subjects. Whereas J{lambda}2/3 genes were employed more often in the patient (58.6%) than in normal subjects (34.5%; p = 0.01), J{lambda}7 was found more frequently in normal subjects (60.0%) than in nonproductive rearrangements of the SLE patient (36.2%; p = 0.011). In general, the usage of J{lambda}1 was significantly less than expected by chance alone regardless of whether nonproductive or productive rearrangements were analyzed.


View this table:
[in this window]
[in a new window]
 
Table II. Distribution of J{lambda} genes in individual B cells from an SLE patient and in normals

 
When the productive repertoires of the patient and the normal subjects were compared, a significantly greater usage of J{lambda}7 was found in the SLE patient than in normal subjects (67.3 vs 54.1%; p = 0.03). Moreover, the frequency of J{lambda}7 was significantly greater in the productive than in the nonproductive repertoire of the SLE patient (67.3 vs 36.2%; p < 0.05).

Distribution of individual V{lambda} genes in B cells from SLE

As shown in Table IIIGo, there were no differences in the distribution of individual V{lambda} genes in the nonproductive repertoire of the SLE patient and the normal donors. When the distribution of particular V{lambda} gene segments in the productive repertoire of the SLE patient was compared with that in the normal subjects, four V{lambda} genes, 2A2 (p = 0.001), 3H (p = 0.045), 1B (p = 0.001), and 4B (p = 0.012), were found significantly less often in the SLE patient. Moreover, a significant over-representation of 3L (p = 0.025), 1G (p = 0.04), 6A (p = 0.001), and 8A (p = 0.001) was found in the productive repertoire of the SLE patient. In general, the over-represented V{lambda} genes in the productive repertoire of the SLE patient tended to be J{lambda} distal. To analyze this in greater detail, the use of V{lambda} genes in the three major gene clusters was assessed (Table IVGo). The usage of the V{lambda} gene clusters, A, B, and C, was similar in the nonproductive repertoires of the patient and the normal subjects. In the productive repertoires, however, the usage of V{lambda} genes of the most J{lambda} proximal cluster, A, was significantly less frequent in the SLE repertoire (33.7%) than in the normal repertoire (48.8%; p < 0.05). Moreover, genes belonging to the most J{lambda} distal cluster, C, were found significantly more frequently in the SLE patient (30.8%) than in normal subjects (14%; p < 0.001). Thus, the productive rearrangements of the SLE patient employed the J{lambda} distal V{lambda} gene cluster C as well as the V{lambda} distal J{lambda}7 gene element significantly more frequently than those of the normal subjects.


View this table:
[in this window]
[in a new window]
 
Table III. Distribution of individual V{lambda} gene usage in an SLE patient and normals

 

View this table:
[in this window]
[in a new window]
 
Table IV. Distribution of V{lambda} gene clusters from individual B cells in an SLE patient compared to normals

 
Mutational frequency

The mutational frequencies of nonproductive and productive V{lambda} rearrangements from the SLE patient were 3.12 and 3.38%, respectively (Table VGo). Thus, there were no major differences between the mutational frequencies of the productive and nonproductive repertoires. Moreover, the nonproductive V{lambda} rearrangements using J{lambda}7 exhibited a mutational frequency of 3.05% compared with a mutational frequency of 3.04% in the productive repertoire. Thus, the distribution of mutations in rearrangements using the most 3'-proximal J{lambda} element was comparable in productive and nonproductive repertoires. This compares with a mutational frequency of 3.43% for nonproductive V{lambda} rearrangements using J{lambda}1–3 and 3.53% for productive rearrangements using J{lambda}1–3. Analysis of mutational frequencies in V{kappa} genes in this patient indicated that productive V{kappa} rearrangements were mutated significantly less than nonproductive V{kappa} rearrangements (2.80 vs 3.60%; p < 0.01). Moreover, productively rearranged V{kappa} genes using the distal J{kappa}5 element were less mutated (1.99%) than rearrangements using J{kappa}1–4 (3.08%; p < 0.001) (3).


View this table:
[in this window]
[in a new window]
 
Table V. Comparison of the overall mutational frequencies between productive and nonproductive V{lambda} and V{kappa} gene rearrangements of the SLE patient

 
TdT activity

Further analysis sought to compare N nucleotide addition at the joins of V{lambda} and J{lambda} elements as an estimate of TdT activity operative on the rearrangements (Table VIGo). Remarkably, in the nonproductive repertoire, there were no J{lambda}7 rearrangements that failed to contain N additions, implying that TdT activity was active during the rearrangement of these gene segments. In the productive repertoire, 20% of rearrangements employing J{lambda}7 exhibited no evidence of TdT activity. The opposite tendency was noted when rearrangements employing J{lambda}1–3 were analyzed, with a higher frequency exhibiting no TdT activity in the nonproductive compared with the productive repertoire. Since TdT activity decreases during B cell ontogeny (12), these results suggested that the productive repertoire may be enriched in J{lambda}7-containing rearrangements that were generated later in ontogeny, as might be anticipated if central receptor editing accounted for their introduction.


View this table:
[in this window]
[in a new window]
 
Table VI. N additions in V{lambda} gene rearrangements of the patient with SLE

 
Distribution of the VH families

A total of 41 productive and six nonproductive VHDJH rearrangements were analyzed. The comparison of the productive VH repertoires between the SLE patient and the normal subjects revealed differences, in that there was a striking over-representation of VH3 family members (82.9 vs 54.9%; p < 0.001) and under-representation of the VH4 family (7.3 vs 22.0%; p < 0.03) in the peripheral B cell repertoire of the SLE patient (Table VIIGo). Of note, members of the VH5, -6, and -7 families were not found in the productive repertoire of the SLE patient, whereas only one VH1 family member (2.4%) and three members of the VH2 family (7.3%) were found.


View this table:
[in this window]
[in a new window]
 
Table VII. Comparison of VH gene family usage in an SLE patient and in normals1

 
Despite obtaining only six nonproductive rearrangements from the SLE patient, the distribution of VH families (Table VIIGo) in the nonproductive repertoire was similar to that in normal subjects. Of note, the ratio of nonproductive/productive rearrangements (0.15%) was identical in the SLE patient and the normal subjects.

JH gene usage

As shown in Table VIIIGo, the distribution of JH genes did not differ between the SLE patient and the normal subjects. In general, JH4 and JH6 dominated the repertoire of productive rearrangements in the SLE patient (53.7 and 22.0%, respectively) and the normal subjects (54.0 and 25.1%, respectively).


View this table:
[in this window]
[in a new window]
 
Table VIII. Distribution of JH genes in individual B cells from an SLE patient and in normals1

 
Usage of individual VH genes

There was a significantly increased usage of VH3-11 in the productive repertoire of the SLE patient (p < 0.001), whereas the frequency of occurrence of all other genes did not differ compared with that in normal subjects. This indicated a preferential expansion of B cells using the VH3-11 element in this patient (see below). Of note, the VH3-11 gene segment has previously been documented to be negatively selected in the normal peripheral B cell repertoire (7).

Detailed analysis of individual gene usage in the nonproductive repertoire of the SLE patient revealed that VH3-08 (p < 0.002), VH3-11 (p < 0.001), and VH3-64 (p < 0.002) were detected significantly more often than in normal subjects (Table IGoX). However, the small number of nonproductive rearrangements from the SLE patient does not permit a firm conclusion, although the significantly increased detection of these three VH genes suggests the possibility of preferential gene usage not seen in normal subjects.

Identification of a clonal expansion of B cells in early, untreated SLE

Sequence analysis of the 8 VH3-11 rearrangements obtained from the SLE patient revealed a high degree of sequence homology in six cases (92.2–99.2%; Fig. 1GoB) consistent with the possibility that B cells expressing this VH3 gene may have derived from of a single B cell precursor. These rearrangements used VH3-11, JH6 and the D elements LR5 and inverse D12/9. The CDR3 length was 45 bp (15aa) and with the exception of putative mutations was identical in each member of the clone. In addition, a productive V{lambda} light chain rearrangement employing V{lambda}1G/J{lambda}7 (Fig. 1Go, A and C) was found in five of these same B cells. The CDR3 length of this V{lambda} rearrangement was 33 bp (11 aa) and was also identical in each clone member, with the exception of putative mutations. In one of the six potential members of this clone, the light chain could not be amplified (D2-2g3E5). The two remaining VH rearrangements using VH3-11 differed from the clone in that two of them used JH4 genes (D2-1g3D11 and D2-1g3E8) with CDR3 lengths of 14 and 8 aa, respectively.



View larger version (35K):
[in this window]
[in a new window]
 
FIGURE 1. A, VH and V{lambda} sequences of the putative progenitor cell of the clone. Bold and underlined letters refer to complementarity-determining regions (CDR) 1, 2, and 3 of each V rearrangement. Each member of the clone expressed the same CDRs, albeit with mutations. B, Mutational tree of clonally related B cells expressing VH3-11. Five sequences employing VH3-11 and JH6 exhibited a striking homology and used the same light chain rearrangement (B) consistent with a clonal relationship. In addition, gene D2-2g3E5/* exhibited VH3-11 sequence homology with the clone, but the light chain could not be amplified. The number in each B cell indicates the total number of mutations, of which the number of mutations shown in the immediate precursor was shared. C, Mutational tree of five sequences employing the V{lambda}1 family member 1G and J{lambda}7 detected in the same cells as the VH sequences shown in A. All rearrangements shared the two mutations detected in D2-2L1 B1.

 
Mutational analysis

The nonproductive VH rearrangements of the SLE patient exhibited a mutational frequency of 6.5% (87 mutations/1330 bp) compared with 4.4% for the productive VH rearrangements (446 mutations/10,172 bp; p < 0.001, by {chi}2 test). Of note, there were only two productively rearranged VH genes (one VH3 and one VH4 family member, respectively) that did not contain nucleotide substitutions, indicating that VH genes of the vast majority of the CD19+ B cells analyzed had undergone somatic hypermutation. The clonally related VH3-11 genes (see Fig. 1GoB) acquired 82 mutations/1446 bp for a mutational frequency of 5.67%. The mutational frequency of the clonally related VH3-11 genes was significantly higher compared with that of the remaining genes (3.7%; p < 0.001).


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The current study analyzed the V{lambda} and J{lambda} as well as the VH and JH gene usage in a patient with SLE and documented that there are few molecular differences apparent in the peripheral B cell repertoire of this patient compared with that of normal controls as indicated by the distribution of V{lambda} and heavy chain genes in the nonproductive repertoires. Analysis of genomic DNA made it possible to obtain a representative number of nonproductive gene rearrangements and thereby permitted the comparison with productive rearrangements.

V{lambda} analysis

Marked differences were noted between the productive V{lambda}J{lambda} gene repertoire of the SLE patient and that of the normal subjects and between the productive and nonproductive repertoires of the SLE patient. These differences could have been attributed to a variety of influences that are dependent on expression of a V{lambda} gene product, including selection and receptor editing.

Detailed analysis of the productive V{lambda} repertoire revealed significant deviations in the distribution of both V{lambda} and J{lambda} elements in the SLE patient compared with normal subjects, in that the frequencies of both the J{lambda} distal V{lambda} elements and the V{lambda} distal J{lambda} segment were increased. In detail, there was an under-representation of the J{lambda} proximal genes, 2A2, 3H, 1B, and 4B in the SLE patient, whereas the J{lambda} distal genes 3L, 1G, 6A, and 8A were over-represented compared with those in normal subjects. This contributed to a significantly different usage of the J{lambda} proximal gene cluster A and the J{lambda} distal V{lambda} gene cluster C between the SLE patient and the controls. The number of V{lambda} genes that exhibited biased representation as well as their locations were most consistent with the conclusion that receptor editing of the V{lambda} locus might have been frequently used in shaping the productive repertoire of the SLE patient. The over-representation of J{lambda}7 in the productive repertoire of the SLE patient was consistent with augmented receptor editing. Analysis of the V{kappa} repertoire of the same patient also revealed evidence of extensive receptor editing of the V{kappa} locus (3). In both circumstances, receptor editing was significantly increased in degree in the SLE patient compared with that in the normal controls.

Despite the evidence that receptor editing of V{kappa} and V{lambda} genes was increased in this SLE patient compared with that in normal subjects, the mechanisms appeared to be different. The data suggested that V{kappa} receptor editing was most marked in the periphery of this SLE patient based on the higher mutational frequency of productive rearrangements employing J{kappa}1–4 compared with those using J{kappa}5 (3). This finding implies that receptor editing of V{kappa} in SLE occurs in the periphery after somatic hypermutation has been initiated. The current analysis supports this conclusion, since productively rearranged V{kappa} genes exhibited a lower frequency of mutations than nonproductive V{kappa} rearrangements. This is markedly different from the situation in normal subjects, in which the mutational frequency of productive V{kappa} rearrangements is significantly greater than that for the nonproductive repertoire (4). This finding implies that receptor editing of V{kappa} rearrangements after mutation is sufficiently robust to result in an overall decrease in the mutational frequency of productive V{kappa} rearrangements in this SLE patient.

The distribution of V{lambda} genes also implied that receptor editing of V{lambda} had occurred in this patient. As opposed to the V{kappa} genes, however, analysis of the mutational pattern suggested that the dominant influence was central, and not peripheral, receptor editing of V{lambda} genes. Thus, there was an increase in the usage of 5' V{lambda} genes and the 3' J{lambda}7 segment, but there was no decrease in the mutational frequency of productive V{lambda} rearrangements using these elements or of the entire productive V{lambda} repertoire. These results imply that the bulk of V{lambda} receptor editing in this SLE patient occurred before the mutational machinery had been activated and therefore most likely occurred in the bone marrow during B cell ontogeny. This contention was supported by an analysis of apparent TdT activity exerted on rearrangements employing J{lambda}1–3 vs J{lambda}7. As TdT activity diminishes during B cell ontogeny (12), it would be anticipated that productive rearrangements that were introduced later in B cell development as a result of receptor editing would contain fewer additions because of waning TdT activity. The increased number of J{lambda}7 containing productive rearrangements with no N segment additions is consistent with this conclusion. The combination of J{lambda}7 containing rearrangements with fewer N nucleotides but a comparable mutational frequency is most consistent with the conclusion that their over-representation in the productive repertoire resulted from central receptor editing.

Whether additional peripheral editing of V{lambda} genes also occurred cannot be determined from this analysis, although it should be noted that if such a process occurred, it was of insufficient magnitude to be detected by this approach. Similarly, we cannot determine whether central receptor editing of V{kappa} rearrangements occurred because peripheral editing was so dominant.

It is noteworthy that recombined V{lambda}4B and J{lambda}2/3 genes were found exclusively in the nonproductive repertoires of both the normal subjects and the SLE patient, suggesting that they were eliminated from the productive gene repertoire of each comparably. This implies that some elements of negative selection or receptor editing operated normally in the SLE patient. Similarly, A30/J{kappa}2 was exclusively found in the nonproductive repertoire of this SLE patient (3). Productively rearranged A30/J{kappa}2 genes have been shown to bind dsDNA in their germline configuration (2, 13). Although the binding specificity of 4B/J{lambda}2/3 gene rearrangements has not been delineated, it was detected only in the nonproductive and not the productive repertoires, suggesting that it might bind an autoantigen. Its elimination from the productive repertoire might, therefore, result from negative selection and/or receptor editing. Whatever the mechanism of elimination, this process appears to be intact in this SLE patient and comparable to that in normal subjects.

Data from V{lambda} transgenic mice have shown that central receptor editing can operate to replace light chains of B cells expressing autoantibodies (14), although there are no previous examples of central receptor editing of V{lambda} chains. There is, however, no conceptual reason that central receptor editing of V{lambda} chains could not occur if these V{lambda} gene products encoded autoantigen recognition. This suggests that emergence of V{lambda}-containing autoantibodies during B cell ontogeny may have been the stimulus for central V{lambda} receptor editing in this SLE patient. In this context, V{lambda} genes have been shown to be critical parts of a number of human autoantibodies, including Abs to dsDNA (15, 16, 17, 18), Abs to La/SS-B and Ro/SS-A (19, 20), rheumatoid factor (21, 22, 23, 24), and Abs to laminin (25), phospholipids (26), collagen, and histone 2A (27). It should be noted, however, that there are insufficient data on the light chain usage of autoantibodies to conclude that receptor editing differentially effects the use of V{lambda} or V{kappa}.

Heavy chain gene usage

In contrast to analyses of VL gene usage in this same patient, the current examination of the VH gene usage revealed no evidence of increased VH receptor editing, but detected other differences in the VH gene repertoire that could contribute to autoantibody formation.

VH gene usage

Receptor editing of the VH gene locus has been observed in a site-directed manner in a transgenic mouse model (28, 29). Defects in receptor editing have been suggested to play a role in retaining autoreactive B cell receptors (BCRs) in autoimmune diseases (29, 30, 31, 32, 33). Despite this, no evidence of abnormalities in receptor editing of VH genes was detected in the current analysis by assessment of the distribution of VH genes, but the possibility that this process is impaired in this SLE patient cannot be completely excluded. Only defects in receptor editing of sufficient magnitude to alter the distribution of VH genes in the productive repertoire were detected. It remains possible that a defect in site-directed receptor editing of VH genes could contribute to autoimmunity in this SLE patient. Of note, however, evidence of enhanced receptor editing of VL chains was easily detected in this patient, making it unlikely that there was an overall defect in the receptor-editing process in this SLE patient.

Comparison of the VH gene usage in the productive repertoire provided evidence that the gene segment VH3-11 was found significantly more often in this SLE patient than in normal subjects. This over-representation was accounted for by the above noted preference to rearrange this germline gene in this patient as well as by the expansion of a B cell clone expressing this VH gene segment. Moreover, other B cells expressing VH3-11 rearranged to other JH segments were also over-represented, suggesting that the negative selection of rearrangements employing VH3-11 observed in normal subjects (7) was disturbed in this patient. Negative selection of VH3-11 in normal subjects has previously been suggested in other studies (34, 35) regardless of the genetic background of the donor. The over-representation of VH3-11 in this SLE patient, therefore, is unusual and mandates an analysis of other SLE patients to determine whether this is a consistent feature of this disease. The possibility that this patient manifested a generalized enhancement in positive selection of VH3-expressing B cells was suggested by the analysis of the entire VH3 family, as well as of the VH3-23 (DP-47) gene. VH3-23 (DP-47) is the most frequently used VH3 family member (6, 7, 34, 35), accounting for 12–14% of the normal repertoire (6). In this SLE patient, VH3-23 was even more frequently used, being expressed by 22% of the B cells. Of importance, VH3-23 has previously been noted to encode anti-DNA Abs frequently, especially the 16/6 Id (36). Whether an abnormal mechanism, such as B cell superantigen stimulation (37, 38), is causing expansion of VH3-expressing B cells in this SLE patient will require carefully analysis of other patients.

One of the remarkable findings of this study is the identification of six B cells that expressed BCRs using VH3-11 and in five cases V{lambda}1G rearrangements with a high degree of sequence homology. Of note, unique patterns of mutations and, with the exception of putative mutations, identical CDR3s were identified, suggesting that these resulted from clonal expansion and Ag-mediated selection. The usage of VH3-11 and V{lambda}1G by this clone requires emphasis, since both genes have been reported to be negatively selected in normal subjects (5, 7). Although proof of autoreactivity of these resulting BCRs is lacking, these data are consistent with the conclusion that clonal expansion of B cells can occur in the initial stages of SLE, suggesting an overwhelming antigenic stimulus. Studies in mice have extensively documented that clonal expression of autoreactive B cells occurs in early lupus (39, 40). In addition, this clone used two D elements, one of which was employed in an inverted orientation. Although the use of inverted D segments has been suggested to increase the frequency of arginines in CDR3s and thereby contribute to the development of anti-dsDNA Abs (41, 42), inverted D elements have also been detected in normal subjects (6, 7). The current data do not allow a firm conclusion about whether an enhanced rate of inverted D elements is a hallmark of clonally expanded B cells in SLE or whether these clones encode anti-DNA Abs. However, the expansion of a B cell clone in the initial stages of SLE in this patient is consistent with findings noted in autoimmune-prone mice (40, 43).

Analysis of mutations provided further insights into the generation of diversity in this SLE patient. The marked degree of somatic hypermutation of the VH rearrangements of this untreated SLE patient is obvious. The mutational frequencies of the CD19+ B cells from the SLE patient (6.5% for nonproductive and 4.4% for productive rearrangements) were significantly greater than those found in normal subjects (CD19+ peripheral B cells from a female Caucasian donor exhibited mutational frequencies of 3.8% for nonproductive and 3.3% for productive rearrangements) (44, 45). Thus, both the nonproductive (p < 0.001) as well as the productive repertoire (p < 0.001) were significantly more mutated in the SLE patient than in normal controls (45). Since previous analyses provided evidence that age influences the number of mutations in memory B cells, we compared the mutations in the 54-yr-old SLE patient with that previously reported in a 45-yr-old male donor (6, 45). The mutational frequency in the SLE patient significantly exceeded that in the nonproductive (p < 0.001) and the productive repertoire (p < 0.005) of this normal donor (nonproductive: 245 mutations/6528 bp; mutational frequency, 3.8%; productive: 1601 mutations/47872 bp; mutational frequency, 3.3%). Since mutational activity, in general, is induced in response to T-dependent Ags, and the frequency of mutations in the nonproductive repertoire reflects the activity of the mutational machinery without subsequent selection (44), the B cells of this patient appear to have been stimulated in a T cell-dependent manner more intensively or more persistently than in normal subjects. Whether this reflects the intensity or persistence of stimulation or a defect in apoptosis of B cells expressing mutated BCRs, as has been suggested (46, 47), remains to be determined. Preliminary data analyzing the mutational frequency of nonproductive V{kappa}k rearrangements revealed a marked increase compared with that in normal subjects (3.6 x 10-2 vs 4.8 x 10-3; p < 0.001). As the mutational frequency of the nonproductive rearrangements is an indication of the immediate impact of the mutator without the subsequent influence of selection or B cell survival, these results are most consistent with the conclusion that the mutational machinery was overactive in this patient.

The difference in the frequency of mutations in the productive and nonproductive repertoires reflects the influence of selection, with elimination of mutation-generated defective BCR normally more evident than positive selection of those with increased avidity (6, 44, 45). This process seems to be generally intact in this SLE patient, even though the overall resulting frequency of mutations in the productive repertoire is much greater than normal.

In summary, skewing of the VH repertoire toward utilization of VH3 genes, clonal expansion of B cells, and a generalized increase in somatic hypermutation may all contribute to the emergence of autoimmunity in this SLE patient. These data are most consistent with the conclusion that extreme B cell overactivity is found in the initial stages of SLE, leading to remarkable changes in peripheral V gene usage and, despite extensive light chain receptor editing, predisposes to the emergence of autoimmunity.


View this table:
[in this window]
[in a new window]
 
Table IX. Distribution of individual VH gene usage in an SLE patient and normals1

 

    Acknowledgments
 
We thank Dr. Qin-Chang Cheng for help in determining appropriate statistical analyses.


    Footnotes
 
1 This work was supported by National Institutes of Health Grant AI 31229 and Deutsche Forschungsgemeinschaft Grants Do 491/2-1 and 4-1 (to T.D.). Back

2 Address correspondence and reprint requests to Dr. Peter E. Lipsky, The Harold C. Simmons Arthritis Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9054. E-mail address: Back

3 Abbreviations used in this paper: SLE, lupus erythematosus; BCR, B cell Ag receptor. Back

Received for publication February 3, 1999. Accepted for publication May 3, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Tan, E. M.. 1989. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44:93.[Medline]
  2. Suzuki, N., T. Harada, S. Mihara, T. Sakane. 1996. Characterization of a germline encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J. Clin. Invest. 98:1843.[Medline]
  3. Dörner, T., N. L. Farner, S. J. Foster, P. E. Lipsky. 1998. Immunoglobulin {kappa} chain receptor editing in systemic lupus erythematosus. J. Clin. Invest. 102:688.[Medline]
  4. Foster, S. J., H. P. Brezinschek, R. I. Brezinschek, P. E. Lipsky. 1997. Molecular mechanisms and selective influences that shape the {kappa} gene repertoire of IgM+ B cells. J. Clin. Invest. 99:1614.[Medline]
  5. Farner, N. L., T. Dörner, P. E. Lipsky. 1999. Distribution of V{lambda} and J{lambda} gene usage in normal individuals. J. Immunol. 162:2137.[Abstract/Free Full Text]
  6. Brezinschek, H.-P., S. J. Foster, R. I. Brezinschek, T. Dörner, R. Domiati-Saad, P. E. Lipsky. 1997. Analysis of the human VH gene repertoire: differential effects of selection and somatic hypermutation on human peripheral CD5+/IgM+ and CD5-/IgM+ B cells. J. Clin. Invest. 99:2488.[Medline]
  7. Brezinschek, H.-P., R. I. Brezinschek, P. E. Lipsky. 1995. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 155:190.[Abstract]
  8. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. Schaller, N. Talal, R. J. Winchester. 1982. The 1982 revised criteria of systemic lupus erythematosus. Arthritis Rheum. 25:1271.[Medline]
  9. Tomlinson, I. M., S.C. Williams, S. J. Corbett, J. B. L. Cox, G. Winter. 1996. V BASE Sequence Directory MRC Centre for Protein Engineering, Cambridge, U.K.
  10. Dörner, T., H.-P. Brezinschek, R. I. Brezinschek, S. J. Foster, R. Domiati-Saad, P. E. Lipsky. 1997. Analysis of the frequency and pattern of somatic mutations within nonproductively rearranged human VH genes. J. Immunol. 158:2779.[Abstract]
  11. Woolson, R. F.. 1987. Statistical Methods for the Analysis of Biomedical Data 337. John Wiley & Sons, New York.
  12. Nussenzweig, M. C., A. C. Shaw, E. Sinn, D. B. Danner, K. L. Holmes, III H. C. Morse, P. Leder. 1987. Allelic exclusion in transgenic mice that express the membrane form of immunoglobulin mu. Science 236:816.[Abstract/Free Full Text]
  13. Harada, T., N. Suzuki, Y. Mizushima, T. Sakane. 1994. Usage of a novel class of germline immunoglobulin variable region gene for cationic anti-DNA autoantibodies in human lupus nephritis and its role for the development of the disease. J. Immunol. 1153:4806.
  14. Radic, M. Z., J. Erikson, S. Litwin, M. Weigert. 1993. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177:1165.[Abstract/Free Full Text]
  15. Roben, P., S. M. Barbas, L. Sandoval, J. M. Lecerf, B. D. Stollar, A. Solomon, G. J. Silverman. 1996. Repertoire cloning of lupus anti-DNA autoantibodies. J. Clin. Invest. 98:2827.[Medline]
  16. Paul, E., A. A. Iliev, A. Livneh, B. Diamond. 1992. The anti-DNA-associated idiotype 8.12 is encoded by the V{lambda}II gene family and maps to the vicinity of L chain CDR1. J. Immunol. 149:3588.[Abstract]
  17. Manheimer-Lory, A. J., M. Irignoyen, B. Gaynor, R. Monhian, A. Splaver, B. Diamond. 1995. Analysis of V{kappa}I and V{lambda}II light chain genes in the expressed B cell repertoire. Ann. NY Acad. Sci. 764:301.[Medline]
  18. Ravirajan, C. T., M. A. Rahman, L. Papdaki, M. H. Griffiths, J. Kalsi, A. C. R. Martin, M. R. Ehrenstein, D. S. Latchman, D. A. Isenberg. 1998. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur. J. Immunol. 28:339.[Medline]
  19. Sestak, A. L., J. B. Harley, S. Yoshida, M. Reichlin. 1987. Lupus/Sjögren’s autoantibody specificities in sera with paraproteins. J. Clin. Invest. 80:138.
  20. Suzuki, H., H. Takemura, M. Suzuki, Y. Sekine, H. Kashiwagi. 1997. Molecular cloning of anti-SS-A/Ro 60 kDa peptide Fab fragments from infiltrating salivary gland lymphocytes of a patient with Sjögren’s syndrome. Biochem. Biophys. Res. Commun. 232:101.[Medline]
  21. Eulitz, M., L. Y. Ch’ang, C. Zirkel, M. Schell, D. T. Weiss, A. Solomon. 1995. Distinctive serologic, chemical, and molecular properties of human lambda IV light chains. J. Immunol. 154:3256.[Abstract]
  22. Ermel, R. W., T. P. Kenny, A. Wong, A. Solomon, P. P. Chen, D. L. Robbins. 1994. Preferential utilization of a novel V{lambda}3 gene in monoclonal rheumatoid factors derived from the synovila cells of rheumatoid arthritis patients. Arthritis Rheum. 37:860.[Medline]
  23. Fang, Q., C. C. Kannapell, F. Gaskin, A. Solomon, W. J. Loopman, S. M. Fu. 1994. Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage of V{lambda}IIIb. J. Exp. Med. 179:1445.[Abstract/Free Full Text]
  24. Solomon, A., D. T. Weiss, C. Murphy, S. M. Fu, D. L. Robbins. 1994. Chemical and serologic characterization of human {lambda}VIII light chains. J. Immunol. 153:1658.[Abstract]
  25. Mariette, X., J. C. Brout, F. Danon, A. Tsapis, K. Lassoued. 1993. Nucleotide sequence analysis of the VL and VH domains of five human IgM directed to laminin B. Arthritis Rheum. 36:1315.[Medline]
  26. Monan, S., M. A. Robman, C. T. Ravirajan, D. Kandiah, C. M. Longhurst, T. McNally, W. M. Williams, D. S. Latchman, D. A. Isenberg. 1997. The production, binding characteristics and sequence analysis of four human IgG monoclonal antiphospholipid antibodies. J. Autoimmun. 10:43.[Medline]
  27. Hatakeyama, A., L. Pricop, N. Kasturi Kuppuswamy, C. A. Bona. 1995. Study of self reactive antibodies in {kappa}-light chain deficient mice. Autoimmunity. 20:113.[Medline]
  28. Chen, C., Z. Nagy, E. Luning-Prak, M. Weigert. 1995. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 3:747.[Medline]
  29. Radic, M. Z., M. Zouali. 1996. Receptor editing, immune diversification, and self-tolerance. Immunity 5:505.[Medline]
  30. Tiegs, S. L., D. M. Russell, D. Nemazee. 1993. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177:1009.[Abstract/Free Full Text]
  31. Radic, M. Z., J. Erikson, S. Litwin, M. Weigert. 1993. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177:1165.
  32. Luning Prak, E., M. Trounstine, D. Huszar, M. Weigert. 1994. Light chain editing in {kappa}-deficient animals: a potential mechanism of B cell tolerance. J. Exp. Med. 180:1805.[Abstract/Free Full Text]
  33. Luning Prak, E., M. Weigert. 1995. Light chain replacement: a new model for antibody gene rearrangement. J. Exp. Med. 182:541.[Abstract/Free Full Text]
  34. Rao, S. P., S. C. Huang, E. C. B. Milner. 1996. Analysis of the VH3 repertoire among genetically disparate individuals. Exp. Clin. Immunogenet. 13:131.[Medline]
  35. Huang, S. C., R. Jiang, A. M. Glas, E. C. B. Milner. 1996. Nonstochastic utilization of Ig V region genes in unselected human peripheral B cells. Mol. Immunol. 33:553.[Medline]
  36. Buskila, D., Y. Shoenfeld. 1992. Manipulation of anti-DNA idiotypes: a possible treatment approach to autoimmune diseases. Concepts Immunopathol. 8:114.[Medline]
  37. Silverman, G. J.. 1998. B cell superantigens: possible roles in immunodeficiency and autoimmunity. Semin. Immunol. 10:43.[Medline]
  38. Domiati-Saad, R., P. E. Lipsky. 1998. Staphylococcal enterotoxin A induces survival of VH3-expressing human B cells by binding to the VH region with low affinity. J. Immunol. 161:1257.[Abstract/Free Full Text]
  39. Ash Lerner, A., M. Ginsberg Strauss, Y. Pewzner Jung, D. D. Desai, T. N. Marion, D. Eilat. 1997. Expression of an anti-DNA-associated VH gene in immunized and autoimmune mice. J. Immunol. 159:1508.[Abstract]
  40. Portanova, J. P., G. Creadon, X. Zhang, D.S. Smith, B. L. Kotzin, L. J. Wysocki. 1995. An early post-mutational event directs expansion of autoreactive B cells in murine lupus. Mol. Immunol. 32:117.[Medline]
  41. Radic, M. Z., M. Weigert. 1995. Origins of anti-DNA antibodies. Ann. NY Acad. Sci. 764:384.[Medline]
  42. Eilat, D., D. M. Webster, A. R. Rees. 1988. V region sequences of anti-DNA and anti-RNA autoantibodies from NZB/NZW F1 mice. J. Immunol. 141:1745.[Abstract]
  43. Wloch, M. K., A. L. Alexander, A. M. Pippen, D. S. Pisetsky, G. S. Gilkeson. 1997. Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. J. Immunol. 158:4500.[Abstract]
  44. Dörner, T., S. J. Foster, H. P. Brezinschek, P. E. Lipsky. 1998. Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. Immunol. Rev. 162:161.[Medline]
  45. Dörner, T., H. P. Brezinschek, S. J. Foster, N. L. R I. Brezinschek, N. L. Farner, P. E. Lipsky. 1998. Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM+/CD5- and IgM+/CD5+ B cells. Eur. J. Immunol. 28:657.[Medline]
  46. Fang, W., B. C. Weintraub, B. Dunlap, P. Garside, K. A. Pape, M. K. Jenkins, C. C. Goodnow, D. L. Mueller, T. W. Behrens. 1998. Self-reactive B lymphocytes overexpressing bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 9:35.[Medline]
  47. Ray, S. K., C. Putterman, B. Diamond. 1996. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc. Natl. Acad. Sci. USA 93:2019.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Burioni, F. Canducci, D. Saita, M. Perotti, N. Mancini, D. De Marco, N. Clementi, A. Chieffo, M. Denaro, D. Cianflone, et al.
Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques
J. Immunol., August 15, 2009; 183(4): 2537 - 2544.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
I Giles, A Lambrianides, and A Rahman
Examining the non-linear relationship between monoclonal antiphospholipid antibody sequence, structure and function
Lupus, October 1, 2008; 17(10): 895 - 903.
[Abstract] [PDF]


Home page
JEMHome page
J. L. Lamoureux, L. C. Watson, M. Cherrier, P. Skog, D. Nemazee, and A. J. Feeney
Reduced receptor editing in lupus-prone MRL/lpr mice
J. Exp. Med., November 26, 2007; 204(12): 2853 - 2864.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
R. L Cassady-Cain and A. K Kaushik
Increased negative selection impairs neonatal B cell repertoire but does not directly lead to generation of disease-associated IgM auto-antibodies
Int. Immunol., May 1, 2006; 18(5): 661 - 669.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. L. Hippen, B. R. Schram, L. E. Tze, K. A. Pape, M. K. Jenkins, and T. W. Behrens
In Vivo Assessment of the Relative Contributions of Deletion, Anergy, and Editing to B Cell Self-Tolerance
J. Immunol., July 15, 2005; 175(2): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Yurasov, H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. C. Nussenzweig
Defective B cell tolerance checkpoints in systemic lupus erythematosus
J. Exp. Med., March 7, 2005; 201(5): 703 - 711.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. Rahman
Autoantibodies, lupus and the science of sabotage
Rheumatology, November 1, 2004; 43(11): 1326 - 1336.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
J. Seagal, E. Edry, H. Naftali, and D. Melamed
Generation and selection of an IgG-driven autoimmune repertoire during B-lymphopoiesis in Ig{micro}-deficient/lpr mice
Int. Immunol., July 1, 2004; 16(7): 905 - 913.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A Rahman, I Giles, J Haley, and D Isenberg
Systematic analysis of sequences of anti-DNA antibodies--relevance to theories of origin and pathogenicity
Lupus, December 1, 2002; 11(12): 807 - 823.
[Abstract] [PDF]


Home page
J. Immunol.Home page
M. R. Edwards, W. Brouwer, C. H. Y. Choi, J. Ruhno, R. L. Ward, and A. M. Collins
Analysis of IgE Antibodies from a Patient with Atopic Dermatitis: Biased V Gene Usage and Evidence for Polyreactive IgE Heavy Chain Complementarity-Determining Region 3
J. Immunol., June 15, 2002; 168(12): 6305 - 6313.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. R. Sekiguchi, S. M. Jainandunsing, M. L. Fields, M. A. Maldonado, M. P. Madaio, J. Erikson, M. Weigert, and R. A. Eisenberg
Chronic Graft-Versus-Host in Ig Knockin Transgenic Mice Abrogates B Cell Tolerance in Anti-Double-Stranded DNA B Cells
J. Immunol., April 15, 2002; 168(8): 4142 - 4153.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Meffre, M. Chiorazzi, and M. C. Nussenzweig
Circulating Human B Cells That Express Surrogate Light Chains Display a Unique Antibody Repertoire
J. Immunol., August 15, 2001; 167(4): 2151 - 2156.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. D. Klonowski and M. Monestier
Heavy Chain Revision in MRL Mice: A Potential Mechanism for the Development of Autoreactive B Cell Precursors
J. Immunol., October 15, 2000; 165(8): 4487 - 4493.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dörner, T.
Right arrow Articles by Lipsky, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dörner, T.
Right arrow Articles by Lipsky, P. E.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS